Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.

Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.

Published version

Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/278135

Repository DOI

https://doi.org/10.17863/CAM.25479

Files

Published version (889.09 KB)

Accepted version (183.35 KB) (Embargoed until: 2100-01-01)

Type

Authors

Vallier, Anne-Laure

Keywords

Humans, Breast Neoplasms, Receptor, erbB-2, Treatment Outcome, Chemotherapy, Adjuvant, Perception, Female, Cardiotoxicity, Surveys and Questionnaires, Trastuzumab, Antineoplastic Agents, Immunological

Journal Title

BMC cancer

Journal ISSN

1471-2407
1471-2407

Volume Title

18

Publisher DOI

https://doi.org/10.1186/s12885-018-4307-8

Rights and licensing

Attribution 4.0 International

Except where otherwised noted, this item's license is described as Attribution 4.0 International

Sponsorship

NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) (HTA/06/303/98)

Collections

Scholarly Works - Oncology